Migraine represents the most common cause of work disability in young women and the
second one in the general population. Preventive treatment can reduce the frequency of …

Objective To evaluate changes in interictal burden with galcanezumab versus placebo in
patients with episodic (EM) or chronic migraine (CM). Background The disruptive effects of …

Introduction Migraine is a leading cause of years lived with disability and preventive
strategies represent a mainstay to reduce health-related disability and improve quality of life …

Background Randomized clinical trials have demonstrated efficacy and safety of erenumab.
The aim of this study is to evaluate the effectiveness and safety of erenumab in a real-world …

Background Migraine is a disabling neurological disease adversely affecting many aspects
of life. Most patients are still required to have failed several older oral preventive therapies …

• Oral medications traditionally used for the prevention of migraine and known to be effective
include anti-epileptic, β-blocker, antihypertensive and antidepressant drugs.• …

Background Galcanezumab has shown efficacy and effectiveness in the treatment of
episodic and chronic migraine (CM), however, the population represented in randomized …

Background: Anti-Calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs)
have shown significant efficacy in preventing migraine. However, there have been limited …

Background Although randomized controlled trials (RCTs) have shown that calcitonin gene-
related peptide (CGRP)-targeted monoclonal antibodies (CGRP mAbs) are an efficacious …

Background Eptinezumab demonstrated efficacy in adults with migraine and prior preventive
treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term …